ZNF23抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P09021(ZNF23 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The zinc finger protein 23 (ZNF23), also known as Kaiso2. is a member of the BTB/POZ-zinc finger family of transcription factors. It plays a regulatory role in gene expression by binding to specific DNA sequences, influencing cellular processes such as proliferation, differentiation, and apoptosis. ZNF23 is implicated in tumor suppression, with studies suggesting its downregulation in cancers like colorectal carcinoma and hepatocellular carcinoma, where it may inhibit epithelial-mesenchymal transition (EMT) and metastasis.

Antibodies targeting ZNF23 are essential tools for investigating its expression patterns, molecular interactions, and functional mechanisms in both normal and pathological conditions. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein levels in tissues or cultured cells. Commercial ZNF23 antibodies are typically raised in hosts like rabbits or mice, with validation data confirming specificity through knockdown/knockout controls.

Current research focuses on ZNF23's dual role in cancer—acting as a tumor suppressor in some contexts while potentially promoting chemoresistance in others. Its antibodies thus serve as critical reagents for exploring therapeutic strategies, biomarker discovery, and understanding ZNF23's interplay with signaling pathways like Wnt/β-catenin. However, variability in antibody performance across experimental conditions underscores the need for rigorous validation in specific applications.